Dicot to develop LIB-01 to an oral drug

Dicot announced in June 2021 that prior to the initial clinical trials in humans, the company intended to evaluate both subcutaneous and oral formulation. Dicot now announces that progress has been made in the development work with the oral formulation. Work with both formulation alternatives will continue, but the company focuses primarily on further developing LIB-01 into an oral drug candidate before start of the phase 1 study. The timetable for start of the first human study needs to be revised to mid-2023.

Prior to the use of an oral formulation in the clinical phase, Dicot will now conduct studies in toxicology, efficacy and duration to relate to previous subcutaneous study data as all previous animal studies have been done with a subcutaneous formulation.

"- The progress we have made with the development of an oral formulation is very satisfying. An oral drug is more convenient for patients and is thus higher valued by the market. In connection with this, we also need to announce a new timetable for starting phase 1 study, but at the same time we are optimizing our negotiating position for future business agreements for out-licensing," says Elin Trampe, CEO of Dicot.